Natriuretic peptides

New England Journal of Medicine

Volumn 339, Issue 5, 1998, Pages 321-328

  Levin, Ellis R ^a   Gardner, David G ^b   Samson, Willis K ^c  

^a VA LONG BEACH HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF NORTH DAKOTA SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR; NATRIURETIC PEPTIDE TYPE C;

ACUTE KIDNEY FAILURE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR EFFECT; CENTRAL NERVOUS SYSTEM FUNCTION; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; HORMONE ACTION; HUMAN; HYPERTENSION; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NATRIURESIS; NEUROENDOCRINOLOGY; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REVIEW;

AMINO ACID SEQUENCE; ATRIAL NATRIURETIC FACTOR; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; CENTRAL NERVOUS SYSTEM; HUMANS; KIDNEY; MOLECULAR SEQUENCE DATA; NATRIURETIC PEPTIDE, BRAIN; NATRIURETIC PEPTIDE, C-TYPE; NERVE TISSUE PROTEINS; PROTEINS; RECEPTORS, ATRIAL NATRIURETIC FACTOR;

EID: 0032581690     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJM199807303390507     Document Type: Review

References (67)

1. de Bold AJ, Borenstein HB, Veress AT, Sonnenberg H. A rapid and potent natriuretic response to intravenous injection of atrial myocardial extracts in rats. Lite Sci 1981;28:89-94.
2. Kangawa K, Matsuo H. Purification and complete amino acid sequence of α-human atrial natriuretic polypeptide (α-hANP). Biochem Biophys Res Commun 1984;118:131-9.
3. Vesely D, Douglass MA, Dietz JR, et al. Three peptides from the atrial natriuretic factor prohormone amino terminus lower blood pressure and produce diuresis, natriuresis, and/or kaliuresis in humans. Circulation 1994;90:1129-40.
4. Gu J, D'Andrea M, Seethapathy M. Atrial natriuretic peptide and its messenger ribonucleic acid in overloaded and overload-released ventricles of rat. Endocrinology 1989;125:2066-74.
5. Saito Y, Nakao K, Arai H, et al. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. J Clin Invest 1989;83:298-305.
6. Schulz-Knappe P, Forssmann K, Herbst F, Hock D, Pipkorn R, Forssmann WG. Isolation and structural analysis of "urodilatin," a new peptide of the cardiodilatin-(ANP)-family, extracted from human urine. Klin Wochenschr 1988;66:752-9.
7. Greenberg RN, Hill M, Crytzer J, et al. Comparison of effects of uroguanylin, guanylin, and Escherichia coli heat-stable enterotoxin STa in mouse intestine and kidney: evidence that uroguanylin is an intestinal natriuretic hormone. J Investig Med 1997;45:276-83.
8. Koller KJ, Goeddel DV. Molecular biology of the natriuretic peptides and their receptors. Circulation 1992;86:1081-8.
9. Maack T, Suzuki M, Almeida FA, et al. Physiological role of silent receptors of atrial natriuretic factor. Science 1987;238:675-8.
10. Charles CJ, Espiner EA, Nicholls MG, et al. Clearance receptors and endopeptidase 24.11: equal role in natriuretic peptide metabolism in conscious sheep. Am J Physiol 1996;271:R373-R380.
11. Charles CJ, Espiner EA, Richards AM. Cardiovascular actions of ANF: contributions of renal, neurohumoral, and hemodynamic factors in sheep. Am J Physiol 1993;264:R533-R538.
12. Lappe RW, Smits JF, Todt JA, Debets JJ, Wendt RL. Failure of atriopeptin II to cause arterial vasodilation in the conscious rat. Circ Res 1985; 56:606-12.
13. Wijeyaratne CN, Moult PJA. The effect of a human atrial natriuretic peptide on plasma volume and vascular permeability in normotensive subjects. J Clin Endocrinol Metab 1993;76:343-6.
14. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. Differing biological effects of equimolar atrial and brain natriuretic peptide infusions in normal man. J Clin Endocrinol Metab 1996;81:3871-6.
15. Schultz HD, Gardner DG, Deschepper CF, Coleridge HM, Coleridge JC. Vagal C-fiber blockade abolishes sympathetic inhibition by atrial natriuretic factor. Am J Physiol 1988;155:R6-R13.
16. Yang RH, Jin HK, Wyss JM, Chen YF, Oparil S. Pressor effect of blocking atrial natriuretic peptide in nucleus tractus solitarii. Hypertension 1992;19:198-205.
17. Itoh H, Pratt RE, Dzau VJ. Atrial natriuretic polypeptide inhibits hypertrophy of vascular smooth muscle cells. J Clin Invest 1990;86:1690-7.
18. Furuya M, Aisaka K, Miyazaki T, et al. C-type natriuretic peptide inhibits intimai thickening after vascular injury. Biochem Biophys Res Commun 1993;193:248-53.
19. Marin-Grez M, Fleming JT, Steinhausen M. Atrial natriuretic peptide causes pre-glomerular vasodilatation and post-glomerular vasoconstriction in rat kidney. Nature 1986;324:473-6.
20. Fried TA, McCoy RN, Osgood RW, Stein JH. Effect of atriopeptin III on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus. Am J Physiol 1986;250:F1119-F1122.
21. Stockand JD, Sansom SC. Regulation of nitration rate by glomerular mesangial cells in health and diabetic renal disease. Am J Kidney Dis 1997; 29:971-81.
22. Harris PJ, Thomas D, Morgan TO. Atrial natriuretic peptide inhibits angiotensin-stimulated proximal tubular sodium and water reabsorption. Nature 1987;326:697-8.
23. Dillingham MA, Anderson RJ. Inhibition of vasopressin action by atrial natriuretic factor. Science 1986;231:1572-3.
24. Sonnenberg H, Honrath U, Chong CK, Wilson DR. Atrial natriuretic factor inhibits sodium transport in medullary collecting duct. Am J Physiol 1986;250:F963-F966.
25. Zeidel ML, Kikeri D, Silva P, Burrows M, Brenner BM. Atrial natriuretic peptides inhibit conductive sodium uptake by rabbit inner medullary collecting duct cells. J Clin Invest 1988;82:1067-74.
26. Light DB, Schwiebert EM, Karlson KH, Stanton BA. Atrial natriuretic peptide inhibits a cation channel in renal inner medullary collecting duct cells. Science 1989;243:383-5.
27. Zeidel ML. Regulation of collecting duct Na+ reabsorption by ANP 31-67. Clin Exp Pharmacol Physiol 1995;22:121-4.
28. Hunt PJ, Richards AM, Espiner EA, Nicholls MG, Yandle TG. Bioactivity and metabolism of C-type natriuretic peptide in normal man. J Clin Endocrinol Metab 1994;78:1428-35.
29. Igaki T, Itoh H, Suga S, et al. C-type natriuretic peptide in chronic renal failure and its action in humans. Kidney Int 1996;49:S144-S147.
30. Saxenhofer H, Raselli A, Weidmann P, et al. Urodilatin, a natriuretic factor from kidneys, can modify renal and cardiovascular function in men. Am J Physiol 1990;259:F832-E838.
31. Morishita Y, Sano T, Kase H, Yamada K, Inagami T, Matsuda Y. HS-142-1, a novel nonpeptide atrial natriuretic peptide (ANP) antagonist, blocks ANP-induced renal responses through a specific interaction with guanylyl cyclase-linked receptors. Eur J Pharmacol 1992;225:203-7.
32. Sano T, Morishita Y, Matsuda Y, Yamada K. Pharmacological profile of HS-142-1, a novel nonpeptide atrial natriuretic peptide antagonist of microbial origin. I. Selective inhibition of the actions of natriuretic peptides in anesthetized rats. J Pharmacol Exp Ther 1992;260:825-31.
33. Honrath U, Matsuda Y, Sonnenberg H. Cardiovascular and renal functional effects of an antagonist of the guanylyl cyclase-linked ANF receptor. Regul Pept 1994;49:211-6.
34. Hirata Y, Maisuuka H, Suzuki E, et al. Rule of endogenous atrial natriuretic peptide in DOCA-salt hypertensive rats: effects of a novel nonpeptide antagonist for atrial natriuretic peptide receptor. Circulation 1993;87:554-61.
35. Wada A, Tsutamoto T, Matsuda Y, Kinoshita M. Cardiorenal and neurohumoral effects of endogenous atrial natriuretic peptide in dogs with severe congestive heart failure using a specific antagonist for guanylate cyclase-coupled receptors. Circulation 1994,89:2232-40.
36. Zhang PL, Mackenzie HS, Troy JL, Brenner BM. Effects of an atrial natriuretic peptide receptor antagonist on glomerular hyperfiltration in diabetic rats. J Am Soc Nephrol 1994;4:1564-70.
37. Angeli P, Jimenez W, Arroyo V, et al. Renal effects of natriuretic peptide receptor blockade in cirrhotic rats with ascites. Hepatology 1994;20:948-54.
38. Levin ER, Isackson PJ, Hu R-M. Endothelin increases atrial natriuretic peptide production in cultured rat diencephalic neurons. Endocrinology 1991;128:2925-30.
39. Levin ER, Hu R-M, Rossi M, Pickart M. Arginine vasopressin stimulates atrial natriuretic peptide gene expression and secretion from rat diencephalic neurons. Endocrinology 1992;131:1417-23.
40. Huang W, Lee D, Yang Z, Copolov DL, Lim AT. Norepinephrine stimulates immunoreactive (ir) atrial natriuretic peptide (ANP) secretion and pro-ANP mRNA expression from rat hypothalamic neurons in culture: effect of α2-adrenoceptors. Endocrinology 1992;130:2426-8.
41. Blackburn RE, Samson WK, Fulton RJ, Stricker EM, Verbalis JG. Central oxytocin and ANP receptors mediate osmotic inhibition of salt appetite in rats. Am J Physiol 1995;269:R245-R251.
42. Burrell LM, Lambert HJ, Baylis PH. Effect of atrial natriuretic peptide on thirst and arginine vasopressin release in humans. Am J Physiol 1991; 260:R475-R479.
43. Samson WK. Recent advances in ANF research. Trends Endocrinol Metab 1992;3:86-90.
44. Steele MK, Gardner DG, Xie PL, Schultz HD. Interactions between ANP and ANG II in regulating blood pressure and sympathetic outflow. Am J Physiol 1991;260:R1145-R1151.
45. Levin ER, Frank HJL. Natriuretic peptides inhibit rat astroglial proliferation: mediation by C receptor. Am J Physiol 1991;261:R453-R457.
46. Langub MC Jr, Dolgas CM, Watson RE Jr, Herman JP. The C-type natriuretic peptide receptor is the predominant natriuretic peptide receptor mRNA expressed in rat hypothalamus. J Neuroendocrinol 1995;7:305-9.
47. Greenwald JE, Sakata M, Michener ML, Sides SD, Needleman P. Is atriopeptin a physiological or pathophysiological substance? Studies in the autoimmune rat. J Clin Invest 1988;81:1036-41.
48. Cao L, Gardner DG. Natriuretic peptides inhibit DNA synthesis in cardiac fibroblasts. Hypertension 1995;25:227-34.
49. Wu CF, Bishopric NH, Pratt RE. Atrial natriuretic peptide induces ap optosis in neonatal rat cardiac myocytes. J Biol Chem 1997;272:14860-6.
50. Burnett JC Jr, Kao PC, Hu DC, et al. Atrial natriuretic peptide elevation in congestive heart failure in the human. Science 1986;231: 1145-7.
51. Gottlieb SS, Kukin ML, Ahern D, Packer M. Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 1989;13:1534-9. [Erratum, J Am Coll Cardiol 1989;14:812.]
52. Motwani JG, McAlpine H, Kennedy N, Struthers AD. Plasma brain nutriuretic peptide as an indicator for angiotensin-converting-enzyme inhibition after myocardial infarction. Lancet 1993;341:1109-13.
53. Stevens TL, Burnett JC Jr, Kinoshita M, Matsuda Y, Redfield MM. A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. J Clin Invest 1995;95:1101-8.
54. Rahman SN, Kim GE, Mathew AS, et al. Effects of atrial natriuretic peptide in clinical acute renal failure. Kidney Int 1994;45:1731-8.
55. Smith JB, Lincoln TM. Angiotensin decreases cyclic GMP accumulation produced by atrial natriuretic factor. Am J Physiol 1987;253:C147-C150.
56. Steinhelper ME, Cochrane KL, Field LJ. Hypotension in transgenic mice expressing atrial natriuretic factor fasion genes. Hypertension 1990;16:301-7.
57. Ogawa Y, Itoh H, Tamura N, et al. Molecular cloning of the complementary DNA and gene that encode mouse brain natriuretic peptide and generation of transgenic mice that overexpress the brain natriuretic peptide gene. J Clin Invest 1994;93:1911-21.
58. John SWM, Krege JH, Oliver PM, et al. Genetic decreases in atrial natriuretic peptide and salt-sensitive hypertension. Science 1995;267:679-81. [Erratum, Science 1995;267:1753.]
59. John SWM, Veress AT, Honrath U, et al. Blood pressure and fluid-electrolyte balance in mice with reduced or absent ANP. Am J Physiol 1996;271:R109-R114.
60. Lopez MJ, Wong SK-F, Kishimoto I, et al. Salt-resistant hypertension in mice lacking guanylyl cyclase-A receptor for atrial natriuretic peptide. Nature 1995;378:65-8.
61. Kishimoto I, Dubois SK, Garbers DL. The heart communicates with the kidney exclusively through the guanylyl cyclase-A receptor: acute handling of sodium and water in response to volume expansion. Proc Natl Acad Sci U S A 1996;93:6215-9.
62. Yokota N, Bruneau BG, Kuroski T, de Bold ML, de Bold AJ. Atrial natriuretic factor significantly contributes to the mineralocorticoid escape phenomenon: evidence for a guanylate cyclase-mediated pathway. J Clin Invest 1994;94:1938-46.
63. Weder A, Sekkarie MA, Takiyyuddin M, Schork NJ, Julius S. Antihypertensive and hypotensive effects of atrial natriuretic factor in men. Hypertension 1987;10:582-9.
64. Fiter MA, Molina CR, Quiroz AC, et al. Hemodynamic and renal effects of atrial natriuretic peptide in congestive heart failure. Am J Cardiol 1990;65:211-6.
65. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acute tubular necrosis. N Engl J Med 1997;336:828-34.
66. Munzel T, Kurz S, Holtz J, et al. Neurohormonal inhibition and hemodynamic unloading during prolonged inhibition of ANF degradation in patients with severe chronic heart failure. Circulation 1992;86:1089-98.
67. Kentsch M, Otter W, Drummer C, Notges A, Gerzer R, Muller-Esch G. Neutral endopeptidase 24.11 inhibition may not exhibit beneficial haemodynamic effects in patients with congestive heart failure. Eur J Clin Pharmacol 1996;51:269-72.